$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion
March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page
FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down
March 14, 2025 On Mar. 5, a judge denied a request from the Outsourcing Facilities Association (OFA), an industry group for compounding pharmacies, to block
Recession Is Coming – But Commercial Diet Companies Could Benefit
March 13, 2025 Marketdata, the parent company of DietBusinessWatch.com, is currently updating its report on the Commercial & Retail Weight Loss Market. Several things have
GLP-1 Drugs Are Affecting Consumers’ Food Spending Habits
March 5, 2025 Weight loss drugs (GLP-1s) have soared in popularity over the last two years, with about 12% of American adults reporting that they’ve
Weight Watchers Reports Q4 and 2024 Yearly Results
Feb. 27, 2025 WW reported its Q4 and full year 2024 results today. The company’s Board of Directors named Interim President and CEO Tara Comonte,
$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report
Feb. 27, 2025 Marketdata LLC has published anew 154-page analysis of the U.S. weight loss market, entitled: “The U.S. Medical Weight Loss Market: The Impact of
Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over
Feb. 25, 2025 Eli Lilly said today that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of
Herbalife Reports 2024 Results, $567 Million Weight Loss U.S. Sales
Feb. 2o, 2025 Herbalife reported Q4 and full year 2024 results. The company sells a significant amount of weight loss and meal replacement products each